Overview
Chronic bacterial endocarditis (CBE) is a serious and often refractory condition characterized by persistent infection of the endocardium, typically involving heart valves or intracardiac devices. Unlike acute endocarditis, which often responds to conventional antibiotic therapy, CBE is marked by its resistance to treatment, often due to the formation of biofilms that shield bacteria from antibiotics and host immune responses. These biofilms can complicate management, necessitating prolonged antibiotic courses or even surgical interventions such as device removal or valve replacement. The pathophysiology of CBE involves complex interactions between microorganisms, host immune defenses, and the structural characteristics of infected tissues, making it a challenging clinical entity to manage effectively.
Pathophysiology
The pathophysiology of chronic bacterial endocarditis is deeply intertwined with the formation of biofilms, which are complex communities of microorganisms encased in a self-produced matrix. These biofilms develop on both native heart valves and prosthetic devices such as catheters and orthopedic implants, significantly complicating treatment strategies [PMID:28851894]. Biofilms provide a protective niche for bacteria, shielding them from both antibiotics and the host immune system. This protection is achieved through physical barriers and the secretion of antimicrobial resistance factors, leading to persistent infection states that are resistant to conventional antibiotic therapy alone. The persistence of these biofilms often necessitates prolonged antibiotic therapy lasting several weeks to months, or in severe cases, surgical intervention such as device removal or valve replacement to eradicate the infection effectively.
In clinical practice, the presence of biofilms underscores the importance of early and aggressive diagnostic approaches to identify CBE promptly. Delayed diagnosis can lead to irreversible damage to cardiac structures and systemic complications, highlighting the critical need for vigilant monitoring and timely intervention. Additionally, the complexity of biofilm formation suggests that therapeutic strategies targeting these structures directly could offer new avenues for improving outcomes in patients with CBE.
Diagnosis
Diagnosing chronic bacterial endocarditis requires a multifaceted approach, combining clinical symptoms, imaging techniques, and laboratory analyses. Common clinical manifestations include persistent fever, weight loss, heart murmurs, and signs of systemic embolization such as stroke or abscess formation. Echocardiography, particularly transesophageal echocardiography (TEE), plays a pivotal role in visualizing vegetations and assessing valve function, providing crucial diagnostic information [PMID:31708017]. Blood cultures remain essential for identifying the causative pathogens, although they can be negative in up to 20% of cases due to intermittent bacteremia or biofilm-associated resistance.
Laboratory findings often include elevated inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), reflecting ongoing inflammation. Microbiological analysis, including molecular techniques like PCR, can aid in detecting fastidious or difficult-to-culture organisms. The diagnostic process must also consider the possibility of mixed infections and the potential for resistant strains, necessitating a comprehensive approach to ensure accurate identification and appropriate management.
Management
The management of chronic bacterial endocarditis is multifaceted, often requiring a combination of prolonged antibiotic therapy, surgical interventions, and emerging therapeutic strategies targeting biofilm persistence. Conventional antibiotic therapy, while foundational, frequently falls short due to biofilm protection mechanisms. Therefore, treatment durations often extend beyond the typical acute endocarditis protocols, sometimes lasting several months to ensure eradication of the infection [PMID:28851894].
Antibiotic Therapy
Prolonged antibiotic therapy tailored to the specific pathogen identified through blood cultures and sensitivity testing is crucial. The choice of antibiotics should cover both common and resistant organisms, potentially including combination therapy to address polymicrobial infections. However, the efficacy of antibiotics alone is often limited by biofilm resistance, necessitating adjunctive treatments.
Surgical Interventions
In cases where medical management fails or significant valvular damage occurs, surgical intervention becomes imperative. This may involve valve replacement, debridement of infected tissues, or removal of infected devices such as prosthetic valves or catheters. Surgical options are particularly critical when there is evidence of irreversible valve dysfunction or persistent infection despite optimal medical therapy [PMID:28851894].
Emerging Therapeutic Approaches
#### Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs), particularly when pre-treated with Toll-like receptor (TLR) agonists such as TLR3 and TLR4, exhibit enhanced antimicrobial properties and immune modulation capabilities. These cells can potentially complement conventional antibiotic therapy by enhancing neutrophil survival and stimulating greater chemokine release, thereby improving the host's immune response against chronic infections [PMID:28851894]. Clinical trials and further research are needed to establish the optimal conditions and protocols for MSC application in CBE, but early evidence suggests a promising synergistic effect with antibiotics.
#### Phage Therapy
Phage therapy represents an innovative approach targeting biofilm-associated infections resistant to conventional antibiotics. Bacteriophages, or phages, are viruses that specifically infect and kill bacteria, making them particularly effective against persistent biofilm infections [PMID:31708017]. Published data supports the efficacy of phages in eradicating chronic infections by directly attacking biofilm structures and persister cells, which are often resistant to antibiotics. While still in the developmental phase for widespread clinical use, phages offer a promising adjunct or alternative therapy, especially in cases of multidrug-resistant pathogens.
Clinical Considerations
In clinical practice, the integration of these emerging therapies requires careful patient selection and monitoring. The potential benefits of MSCs and phages must be weighed against potential risks, including immune reactions and the need for personalized treatment protocols. Collaboration between infectious disease specialists, cardiologists, and surgeons is essential to tailor the most effective treatment plan for each patient, balancing the need for aggressive intervention with the risks associated with prolonged therapy and invasive procedures.
Complications
Chronic bacterial endocarditis is fraught with numerous complications, many of which stem from the persistent nature of biofilm infections. Systemic embolization, leading to conditions such as stroke, peripheral emboli, and abscess formation, is a significant concern [PMID:31708017]. These complications arise when bacterial emboli detach from vegetations and travel through the bloodstream, causing damage to distant organs. Additionally, the chronic inflammation associated with CBE can result in valvular dysfunction, heart failure, and arrhythmias, further complicating patient outcomes.
Biofilm persistence exacerbates these complications by continuously harboring bacteria, making them resilient to conventional treatments. This resilience not only prolongs the infection but also increases the risk of recurrent episodes and treatment failure. Emerging therapies targeting biofilms, such as phages, hold potential in mitigating these complications by directly addressing the root cause of persistent infection. By effectively disrupting biofilm structures, these treatments could reduce the incidence of systemic embolization and improve overall cardiac function, thereby enhancing patient prognosis and quality of life.
Key Recommendations
These recommendations aim to provide a comprehensive framework for managing chronic bacterial endocarditis, integrating both established and emerging therapeutic strategies to improve patient outcomes.
References
1 Johnson V, Webb T, Norman A, Coy J, Kurihara J, Regan D et al.. Activated Mesenchymal Stem Cells Interact with Antibiotics and Host Innate Immune Responses to Control Chronic Bacterial Infections. Scientific reports 2017. link 2 Abedon ST. Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. Advanced drug delivery reviews 2019. link
2 papers cited of 3 indexed.